Bionomics announces amended exchange ratio for re-domicile merger; court approves Dec 12 meeting

Neuphoria Therapeutics Inc.

Amended exchange ratio: 1 Neuphoria share per 2,160 Bionomics ordinary shares; 1 per 12 ADSs.
Supreme Court of New South Wales approved convening of shareholder meeting on Dec 12, 2024.
Bionomics has Nasdaq minimum bid price deficiency notice; expects compliance after scheme completion.
Re-domicile from Australia to Delaware; Neuphoria common stock to list on Nasdaq.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.